Leadership

Ronald Christensen

Dr. Christensen has broad-based experience in academia, clinical research, and the biopharmaceutical industry.Following his fellowship training in Pediatric Endocrinology, he was Director of Endocrinology at Phoenix Children’s Hospital.As a Director in both the Marketing and Medical Affairs Departments at Genentech, Inc., he provided expertise in development of observational studies to support clinical, safety, and product commercialization efforts. He was responsible for the design, implementation, and management of several patient registries in various therapeutic areas over a 10-year period.

As Senior Director of Medical Affairs at Genentech, Dr. Christensen was responsible for the management and direction of four groups: Medical Information, Drug Safety, Epidemiology, and Post-marketing Studies. These groups provided customer and product support for commercial products and were involved in the clinical development of new molecular entities.

In 1986, Stephen Webb and Dr. Christensen founded a contract research organization (CRO) focused on conducting peri- and post-approval studies that later became REGISTRAT^®, Inc. In June 2009, REGISTRAT merged with a MAPI Group company to form REGISTRAT-MAPI, a global Late Phase CRO.In addition to his role as a member of the Executive Committee, his administrative responsibilities as Co-CEO include strategic oversight of North America business and operations and direct management of the Quality Assurance, Human Resources, Information Technology, and Business Development Departments.

During his 25 years in the biopharmaceutical industry, Dr. Christensen has become an industry leader in the development and application of Late Phase studies (peri- and post-approval studies) for post-marketing safety surveillance, clinical effectiveness, outcomes research, and risk management.He has been involved in the strategic design, implementation, and management of hundreds of Late Phase studies and Risk Management Programs.

William C. Maier

Dr. William C. Maier, is Vice President Epidemiology, Drug Safety, and Risk Management at REGISTRAT-MAPI the industry's largest clinical research organization (CRO) dedicated solely to real-world clinical research.

Dr. Maier has over 20 years of experience in drug development and commercialization at pharmaceutical companies in Europe and the United States. He was previously Senior Director of Epidemiology at GlaxoSmithKline and Elan Pharmaceuticals and led research groups conducting observational research using registries, databases, chart reviews and field research to support reimbursement, marketing and drug safety investigations of pharmaceuticals throughout the world. He has worked on over 50 observational studies in several disease areas including respiratory, neurology, psychiatry, autoimmune, cancer, endocrinology, cardiovascular, cerebrovascular, urology, opioid dependency and vaccines.

He routinely provides training seminars to pharmaceutical, biotechnology and medical products companies in Europe and the United States on the use and development of real-life data for use in health technology assessment, drug safety and risk management. In July 2007 he presented the Tysabri Risk Management Plan at an FDA advisory committee meeting.

Dr. Maier is editor of the quarterly PharmacoEpi and Risk Management Newsletter, (http://www.prmnewsletter.org/) which publishes articles on applications of methods, development of new tools and reflections on regulatory developments in product safety, pharmacoepidemiology and risk management.

He is also involved with the International Society of Pharmacoeconomics Research (ISPOR) project to develop a global database of real-life health care information (www.ispor.org/Intl_Databases/) and is a member of the EMEA's European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (www.encepp.eu). In addition, he is a frequent speaker at medical conferences and has academic appointments in the UK (Dundee) and the USA (North Carolina).

Stephen Webb

Mr. Webb is responsible for business and global operations, strategic consultation on study design and analyses, international affiliates, product commercialization, and client and business development activities for the company. Mr. Webb has been in the industry since 1988 marketing biopharmaceuticals, conducting clinical and basic research, and developing numerous peri- and post-approval studies including: Phase IIIb–IV studies; disease, product, and pregnancy registries; post-marketing commitment studies; and expanded safety surveillance and risk management programs.

Mr. Webb has held previous positions at Glaxo Pharmaceuticals, Research Triangle Park, NC as a Hospital/Field Sales Representative where he marketed oral and parenteral gastro-infectious disease and neurological pharmaceuticals, and ClinTrials Research where he managed Phase II–IV clinical studies for FDA submission and approvals with a concentration in Phase IV Post-Marketing Studies.

Mr. Webb is a graduate of the University of Kentucky where he majored in Business Administration and Biology, completed his premedical curriculum, and conducted basic research at the Center for Biomedical Engineering and Department of Anatomy and Neurobiology. Mr. Webb is a Fellow of the Howard Hughes Medical Institute, has authored published abstracts and scientific papers, and presents at numerous industry conferences.

Hubert Méchin

Trained as a general physician, Hubert Méchin practiced general medicine for five years and complemented his training with a Master's degree in Health Marketing from the University of Paris IV. His career in the pharmaceutical industry began in 1992 in Medical Products for MSD Laboratories where he spent two years. He then entered into the service performance field for the pharmaceutical industry starting as a Project Manager and later Project Director for a European CRO (FDM Pharma) where he developed a department dedicated to observational studies.

In 1998 he created his own enterprise (NAXIS) which was entirely dedicated to observational and Pharmaco-epidemiology studies. In 2001, NAXIS joined MAPI Group where he developed the Late Phase activity on both national and international levels. Hubert Méchin is a guest lecturer for numerous continued education courses (Master of Health Marketing at the University of Paris IV, Pharmaco Epidemiology degree programs at the University of Lyon I, and Pharmaco-Epidemiology symposiums and conferences) and in 2004 created the Summer University of Pharmaco-Epidemiology (UPE). Additionally, Hubert Méchin is the Vice-President of the French Association of CRO's (AFCROs).

Bernard Jambon

After earning his Masters degree in Law and Economics, and a year as a basketball player in the UK, Bernard Jambon founded MAPI in 1974. In 1981, he was joined by Jean-Louis Ménard.

Today, Mr. Jambon is associate chairman and CEO of MAPI Group, a world leader in Late Phase clinical trials, Pharmaco-Epidemiology and Market Access. MAPI Group focuses on drug evaluation studies with a specific emphasis on patient assessment and Late Phase evaluation.

Mr. Jambon was a teacher at the Lyon Business School (ESC) in 1976. He is founder and editor of the “PRO Newsletter” and “PRM Newsletter”. He is a member of the editorial board of the “Journal of Epidemiology and Biostatistics.” Mr. Jambon previously served on the Advisory Council of Europe for the Drug Information Association and on the Board of Directors of ISOQOL.